Journal ArticleDOI
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Reads0
Chats0
TLDR
Dulaglutide could be considered for the management of glycaemic control in middle-aged and older people with type 2 diabetes with either previous cardiovascular disease or cardiovascular risk factors.About:
This article is published in The Lancet.The article was published on 2019-07-13. It has received 1449 citations till now. The article focuses on the topics: Dulaglutide & Placebo-controlled study.read more
Citations
More filters
Journal ArticleDOI
Metabolic effects of antihyperglycemic agents and mortality: meta-analysis of randomized controlled trials.
Dimitris Rucks Varvaki Rados,Camila Viecceli,Lana Catani Ferreira Pinto,Fernando Gerchman,Cristiane Bauermann Leitão,Jorge Luiz Gross +5 more
TL;DR: Medications with better metabolic profile were associated with reduced all-cause and cardiovascular mortality, and these findings are based on indirect comparisons and must be applied cautiously.
Journal ArticleDOI
Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists
TL;DR: Evidence supporting the use of GLP-1RAs for stroke reduction in people with type 2 diabetes is summarized and 2 new resources are offered—a list of frequently asked questions with evidence-based answers on safely initiating and managing GLP (glucagon-like peptide 1 receptor agonists) and a practical decision-making algorithm to assist in usingGLP- 1RAs as part of a stroke reduction strategy.
Journal ArticleDOI
Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023
TL;DR: The Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) as discussed by the authors is intended to provide clinicians an overview of type 2 diabetes mellitus (T2DM), an obesity-related cardiometabolic risk factor.
Journal ArticleDOI
Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: A nationwide observational study
TL;DR: In this paper, the authors used Cox regression analysis with estimated hazard ratios (HRs) adjusted for confounders with 95% confidence intervals (CIs) to determine if incretin treatment decreases the risk of stent-thrombosis and/or in-stent restenosis after percutaneous coronary intervention (PCI) with implanted drug-eluting stents (DES).
Journal ArticleDOI
Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus
Malik Elharram,Abhinav Sharma,William B. White,George L. Bakris,Patrick Rossignol,Cyrus R. Mehta,João Pedro Ferreira,Faiez Zannad +7 more
TL;DR: In a contemporary cohort of T2DM with a recent ACS, the risk for recurrent CV events including MI and HF hospitalization is elevated early after an ACS, and future studies evaluating the initiation of antihyperglycemic therapies in the early period following an ACS are warranted.
References
More filters
Journal ArticleDOI
A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation
TL;DR: The purpose of this study was to develop an equation from MDRD Study data that could improve the prediction of GFR from serum creatinine concentration, and major clinical decisions in general medicine, geriatrics, and oncology are made by using the Cockcroft-Gault formula and other formulas to predict the level of renal function.
Journal ArticleDOI
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Jason P. Fine,Robert Gray +1 more
TL;DR: This article proposes methods for combining estimates of the cause-specific hazard functions under the proportional hazards formulation, but these methods do not allow the analyst to directly assess the effect of a covariate on the marginal probability function.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
TL;DR: The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.
Journal ArticleDOI
Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.
Andrew S. Levey,Josef Coresh,Tom Greene,Lesley A. Stevens,Yaping (Lucy) Zhang,Stephen Hendriksen,John W. Kusek,Frederick Van Lente +7 more
TL;DR: The MDRD Study equation has now been reexpressed for use with a standardized serum creatinine assay, allowing GFR estimates to be reported in clinical practice by using standardized serumcreatinine and overcoming this limitation to the current use of GFR estimating equations.
Journal ArticleDOI
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso,Gilbert H. Daniels,Kirstine Brown-Frandsen,Peter Lommer Kristensen,Johannes F.E. Mann,Michael A. Nauck,Steven E. Nissen,Stuart J. Pocock,Neil R Poulter,Lasse Steen Ravn,William M. Steinberg,Mette Stockner,Bernard Zinman,Richard M. Bergenstal,John B. Buse +14 more
TL;DR: In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, orNonfatal stroke among patients with type 2 diabetes mellitus was lower with liraglutide than with placebo.